Evidence map›Paper›PMID 35318165›Full record

ArticleBioorganic & medicinal chemistry letters2022

Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals.

Marina Fosso Yatchang, Bini Mathew, Ritesh K Srivastava, Jasim Khan, Suhail Muzaffar, Sixue Zhang, Mousheng Wu, Ling Zhai, Pedro Ruiz, Anupam Agarwal and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Marina Fosso YatchangScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Bini MathewScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Ritesh K SrivastavaUAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Jasim KhanUAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Suhail MuzaffarUAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Sixue ZhangScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Mousheng WuScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Ling ZhaiScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Pedro RuizScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Anupam AgarwalUAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
James R BostwickScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Mark J SutoScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
Mohammad AtharUAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: mohammadathar@uabmc.edu.
Corinne E Augelli-SzafranScientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA. Electronic address: caugelli-szafran@southernresearch.org.
Southern Research Institute · USUniversity of Alabama at Birmingham · US

Funding

UAB Research Center of Excellence in ArsenicalsU54ES030246 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMAD, AFTAB · 2018 to 2022
$19.0M
NIEHS NIH HHS U54 ES030246
6 · The paper itself

Abstract

Arsenicals belong to the class of chemical warfare agents known as vesicants, which are highly reactive, toxic and cause robust inflammatory response. Cutaneous exposure to arsenicals causes a wide range of systemic organ damage, beginning with cutaneous injuries, and later manifest multi-organ damage and death. Thus, the development of suitable antidotes that can effectively block injury following exposure to these agents is of great importance. Bromodomain 4 (BRD4), a member of the bromodomain and extra terminal domain (BET) family, plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. In this context, the development of potent small molecule inhibitors of BRD4 could serve as potential antidotes for arsenicals. Herein, we describe the synthesis and biological evaluation of a series of compounds.

Indexed as

ArsenicalsAntidotesAnti-Inflammatory AgentsNuclear ProteinsTranscription FactorsAntidotesAnti-Inflammatory AgentsArsenicalsNuclear ProteinsTranscription FactorsAntidotesArsenicalsBromodomain 4Inflammation

Identifiers

PMID35318165
PMCPMC9017782
OpenAlexW4220952401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.